The purpose of this study is to determine the safety and effectiveness of the study drug, HP802-247 (a suspension of keratinocytes in a fibrin matrix), in healing venous leg ulcers as compared to the fibrin matrix alone.
Males/Females 18 years of age and older with a venous leg ulcer.
Up to 22 weekly clinic visits (depending on when or if your wound heals), followed by up to six follow-up clinic visits every eight weeks until you have completed one full year of study participation.
You will be in the study approximately 12 months.
You may contact Tiffany Whitaker, 217-545-2320 or email email@example.com.
Doug Hood, MD